Sunwin Stevia International Past Earnings Performance
Past criteria checks 0/6
Sunwin Stevia International has been growing earnings at an average annual rate of 11.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 13.3% per year.
Key information
11.8%
Earnings growth rate
11.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 13.3% |
| Return on equity | -126.6% |
| Net Margin | -7.0% |
| Last Earnings Update | 31 Jul 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sunwin Stevia International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 22 | 37 | -3 | 4 | 3 |
| 30 Apr 22 | 35 | -3 | 4 | 3 |
| 31 Jan 22 | 34 | -4 | 4 | 2 |
| 31 Oct 21 | 30 | -4 | 3 | 2 |
| 31 Jul 21 | 25 | -3 | 3 | 1 |
| 30 Apr 21 | 25 | -3 | 3 | 1 |
| 31 Jan 21 | 25 | -2 | 3 | 2 |
| 31 Oct 20 | 24 | -2 | 3 | 2 |
| 31 Jul 20 | 26 | -2 | 3 | 2 |
| 30 Apr 20 | 26 | -1 | 3 | 2 |
| 31 Jan 20 | 25 | -3 | 3 | 2 |
| 31 Oct 19 | 25 | -2 | 4 | 1 |
| 31 Jul 19 | 23 | -4 | 4 | 1 |
| 30 Apr 19 | 21 | -5 | 5 | 1 |
| 31 Jan 19 | 20 | -4 | 4 | 1 |
| 31 Oct 18 | 20 | -3 | 4 | 1 |
| 31 Jul 18 | 20 | -4 | 4 | 1 |
| 30 Apr 18 | 19 | -4 | 5 | 1 |
| 31 Jan 18 | 18 | -5 | 5 | 1 |
| 31 Oct 17 | 18 | -5 | 5 | 1 |
| 31 Jul 17 | 19 | -4 | 6 | 1 |
| 30 Apr 17 | 19 | -4 | 6 | 0 |
| 31 Jan 17 | 22 | -5 | 6 | 0 |
| 31 Oct 16 | 20 | -6 | 5 | 1 |
| 31 Jul 16 | 17 | -5 | 5 | 1 |
| 30 Apr 16 | 18 | -5 | 5 | 1 |
| 31 Jan 16 | 17 | -6 | 6 | 1 |
| 31 Oct 15 | 18 | -4 | 6 | 0 |
Quality Earnings: S1N is currently unprofitable.
Growing Profit Margin: S1N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: S1N is unprofitable, but has reduced losses over the past 5 years at a rate of 11.8% per year.
Accelerating Growth: Unable to compare S1N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: S1N is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: S1N has a negative Return on Equity (-126.6%), as it is currently unprofitable.